A “booster” of biopharmaceutical projects
CVASTHERA
OUR GOAL
“Reimagining innovative molecules or projects for improving patient's lives”.
WHO WE ARE ?

CVasThera was founded in 2016 by highly experienced pharmaceutical industry professionals, with a world-class track record of CV drug discovery, drug development, clinical trials, and company management. We are experienced professionals in pre-clinical and clinical development who know that there is a better way to develop drugs.

Our team
Bruno LE GRAND
President, PhD, Co-founder
Biotechnology executive with over 30 years experience in biopharma, health care and industrial biotechnology.
Sylvie Le grand
Chief Operating Officer, Co-founder
Pharmaceutical research over 20 years experience followed by 10 years of clinical trial management.
"Our business model for an optimal development program is based on 4 keys"
01

Access to appropriate Expertise scientific

New identified compound or target molecule is of high interest, but it is often just a first step in a long process that will determine the potential of this compound or a related congener to be developed into an authority-approved drug. Many of the early clincial trials are performed with a drug known to work safely in one indication, to support a new label expansion but integrative physiology and/or pharmacology is oftenly bypassed. Integrate biological, chemical and pharmacological data to help drive innovation and support earlier decision-making when developing new hypotheses around targets, drugs, and how to translate animal models into humans is our area of expertise.

02

Access to appropriate funding

While basic discovery research is funded primarily by government and by philanthropic organizations, early-stage development is funded mainly by pharmaceutical companies or venture capitalists. At CVasThera, we are dedicated to accelerating innovation and advancing science at early-stage development. That’s why we want to foster independent research by reducing financial hurdles for researchers.

03

Access to fast timelines to clinical proof of concept

Proof-Of-Concept (POC) is a pivotal milestone in the drug development process. In front of the failure number, the early development processes must be re-engineered to improve R&D productivity and shorten project timelines, whilst at the same time allowing a more flexible and interrogative investigation of a drug candidates unique potential. Based on long experiences , CVasThera was dedicated to evaluating integrated and adaptive clinical protocols combining healthy volunteer and POC investigations.

04

Intellectual property strategy «Patent»

Patent protection for pharmaceutical products in the developing world can help to encourage the development of new medicines for diseases that affect these countries, by providing protection for the investments that need to be made by the pharmaceutical companies. Pharmaceutical companies often maintain that patent protection for drugs ensures that they are able to invest billions of dollars into the development of new products, by making sure that they will be able to take advantage of the sales. Based on long experiences , CVasThera was dedicated to assure the innovation of new proposal patents.

What we do ? & How we work
01 Identification
We acquire drugs and transform them into differentiated therapeutics that improve patients’ lives.
02 Optimization
We monitor projects from concept to realisation and provide our expertise.
03 Clinical results
We make drug efficient.
PORTFOLIO

The expertise of CVasThera is engaged in promising projects.

PARTNERING
Creating value together

Together we go further faster. We value collaboration vs competition. We reach out to potential partners worldwide who share our values and commitment to global health.

Prof. David Garcia Dorado
MD, PhD
Head, Cardiology Department, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona.
Prof. Stéphane N. Hatem
MD, PhD
Director of Research at INSERM and Full Professor of Physiology at the Pitié, Salpêtrière Hospital and at UPMC Paris.
Prof. James Gillespie
BSc, PhD
Professor of Human Physiology, Newcastle University, England. Visiting Professor of Physiology, Department of Urology, Antwerp University, Belgium.
Dr. Nathalie Vergnolle
PhD
Director of Research at INSERM at Toulouse.
Fresh news
December 22Th 2017 CVasThera engaged in a new treatment for atrial fibrillation

CVasThera signs an agreement that provide expertise to Boston Pharma relating to BOS1728515 program in pre-clinical or clinical development for the treatment of postoperative atrial fibrillation...

by Boston Pharmaceutical
January 26Th 2018 CVasThera, a partner for a new treatment in acute myocardial infarction

CVasThera signs an agreement that provide, expertise to the OP2drugs relating to OP2113 program in pre-clinical development for the treatment of acute myocardial infarction...

by OP2
July 13Th 2018 A new step for CVasThera : «Credit Impôt Recherche » CIR

The french ministry of Education, Research and Innovation has approved CVasThera for the CIR. With this agreement, CVasThera has been now recognized skillful for performing R&D projects in France for the three next years...

by CIR
August 1ST 2018 A growing patnership between OP2 drugs and CVasthera

OP2 drugs appoints Bruno LE GRAND chief scientifical officer...

by OP2 & CVasThera
2 October 2018 CVasThera engaged in crohn disease (CD)

CVasThera has received a grant research from "Région Occitanie" to advance development of CVT12011965 a promising candidate for treatment of crohn disease (CD). The grant will support research studies carried out by INSERM Toulouse and for the develpment an innovative galenic form carried out by GALA castres.

by Boston Pharmaceutical
You want to meet CVasThera ? Contact us